<?xml version="1.0" encoding="UTF-8"?>
<p>Furthermore, it was only in 1982, when modern recombinant techniques enabled the production of synthetic surface antigens of the hepatitis B virus (
 <xref rid="B22" ref-type="bibr">22</xref>) and of the HPV L1-derived virus-like particles (
 <xref rid="B23" ref-type="bibr">23</xref>) that compose the HPV vaccine, which only started to be used in 2010 (
 <xref rid="B2" ref-type="bibr">2</xref>).
</p>
